StreetInsider.com News Articles

Form DEF 14A DAXOR CORP For: Jun 03

Wed, 03 Jun 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260603/26599102.html

Form DEF 14A DAXOR CORP For: Jun 03

Wed, 03 Jun 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260603/26599102.html

Daxor receives US patent for remote blood volume monitoring technology

Tue, 02 Jun 2026 08:04:24 -0400

Daxor Corporation (NASDAQ: DXR) announced the United States Patent and Trademark Office issued U.S. Patent No. 12,635,917 B2 for its "Remote Blood Volume Monitor" technology.

The patent covers systems and methods for ongoing remote monitoring of patient blood volume status after an initial baseline measurement. The technology integrates hematocrit monitoring through non-invasive optical sensors, including photo-plethysmography embedded in smartwatches and wearable devices, with Daxor's blood volume analysis algorithms.

The system provides real-time updates on total blood volume, plasma volume, and red cell volume without requiring repeated tracer injections. It calculates volume deviations and triggers clinical notifications when fluid or red cell levels

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

Tue, 02 Jun 2026 08:00:00 -0400

New Technology Expands Daxor’s Diagnostic Capabilities to Enable Continuous, Remote Tracking of Blood Volume Status Using Wearable Sensors, Enhancing Care for Heart Failure, Syncope, Anemia, and Polycythemia

OAK RIDGE, TN, June 02, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,635,917 B2, titled “Remote Blood Volume Monitor.”

The newly issued patent covers innovative systems and methods for the ongoing and remote monitoring of a patient’s absolute blood volume status

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

Tue, 02 Jun 2026 08:00:00 -0400

The newly issued patent covers innovative systems and methods for the ongoing and remote monitoring of a patient’s absolute blood volume status

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

Tue, 02 Jun 2026 08:00:00 -0400

The newly issued patent covers innovative systems and methods for the ongoing and remote monitoring of a patient’s absolute blood volume status

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

Tue, 02 Jun 2026 08:00:00 -0400

The newly issued patent covers innovative systems and methods for the ongoing and remote monitoring of a patient’s absolute blood volume status

Form NT NPORT-P DAXOR CORP For: Mar 31

Tue, 02 Jun 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260602/26586819.html

Form NT NPORT-P DAXOR CORP For: Mar 31

Tue, 02 Jun 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260602/26586819.html

Form 40-8F-2/A DAXOR CORP

Thu, 21 May 2026 15:42:00 -0400

si-local-file:///var/storage/secattach/20260521/26534886.html

Form 40-8F-2/A DAXOR CORP

Thu, 21 May 2026 15:42:00 -0400

si-local-file:///var/storage/secattach/20260521/26534886.html

Form 40-17F2 DAXOR CORP Filed by: DAXOR CORP

Mon, 11 May 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260511/26464225.html

Form 40-17F2 DAXOR CORP Filed by: DAXOR CORP

Mon, 11 May 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260511/26464225.html

Form 40-17F2 DAXOR CORP Filed by: DAXOR CORP

Wed, 06 May 2026 11:57:00 -0400

si-local-file:///var/storage/secattach/20260506/26441889.html

Form 40-17F2 DAXOR CORP Filed by: DAXOR CORP

Wed, 06 May 2026 11:57:00 -0400

si-local-file:///var/storage/secattach/20260506/26441889.html

Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis

Tue, 28 Apr 2026 08:00:00 -0400

Oak Ridge, TN, April 28, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will exhibit its Blood Volume Analyzer (BVA™) technology at the MedAxiom CV Transforum Spring’26 Conference. The event, being held at the Sawgrass Marriott Golf Resort & Spa, Ponte Vedra Beach, FL, from April 30 – May 2, 2026, is a premier venue for cardiovascular thought leaders and industry innovators to drive the future of cardiac care delivery.

The CV Transforum serves as a strategic touchpoint for Daxor

Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis

Tue, 28 Apr 2026 08:00:00 -0400

The CV Transforum serves as a strategic touchpoint for Daxor

Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis

Tue, 28 Apr 2026 08:00:00 -0400

The CV Transforum serves as a strategic touchpoint for Daxor

Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis

Tue, 28 Apr 2026 08:00:00 -0400

The CV Transforum serves as a strategic touchpoint for Daxor

Form 4 DAXOR CORP For: Apr 08 Filed by: Feldschuh Michael Richard

Fri, 10 Apr 2026 13:54:00 -0400

si-local-file:///var/storage/secattach/20260410/26299346.html

Form 4 DAXOR CORP For: Apr 08 Filed by: Feldschuh Michael Richard

Fri, 10 Apr 2026 13:54:00 -0400

si-local-file:///var/storage/secattach/20260410/26299346.html

Daxor launches blood volume testing program at Ohio cardiology center

Wed, 08 Apr 2026 08:01:40 -0400

Daxor Corporation (NASDAQ: DXR) announced the launch of a new blood volume analysis program at a cardiology facility in Southwest Ohio. The program utilizes Daxor's ezBVA Lab workflow to provide 24-hour turnaround times for blood volume measurements without requiring onsite laboratory infrastructure.

The Tennessee-based company's lab-as-a-service model allows the cardiology center to access blood volume testing for heart failure patients. The service uses existing reimbursement codes and eliminates the need for capital investment in laboratory equipment.

"We are enabling clinicians to move the standard of care from proxy markers and subjective assessment of volume status to data-driven precision," said Michael Feldschuh, Daxor's

Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center

Wed, 08 Apr 2026 08:00:00 -0400

Oak Ridge, TN, April 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion with the launch of a new BVA program at a premier cardiology facility in Southwest Ohio. This integration brings Daxor’s state-of-the-art testing to a high-volume heart failure care setting, targeting the growing market for chronic disease management.

By leveraging Daxor’s proprietary, Tennessee-based ezBVA Lab workflow, the facility gains access to 24-hour turnaround on gold-standard blood volume metrics without the need for onsite laboratory infrastructure. This "lab-as-a-service" model

Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center

Wed, 08 Apr 2026 08:00:00 -0400

Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center

Wed, 08 Apr 2026 08:00:00 -0400